tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KZIA Stock Latest News

Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
The FlyKazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
5d ago
KZIA
Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
PremiumCompany Announcements
Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
6d ago
6K
KZIA
Kazia Therapeutics announces presentation from paxalisib studies
PremiumThe Fly
Kazia Therapeutics announces presentation from paxalisib studies
7d ago
KZIA
Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance
PremiumCompany Announcements
Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance
11d ago
6K
KZIA
Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development
PremiumCompany Announcements
Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development
14d ago
6K
KZIA
Kazia Therapeutics trading resumes
PremiumThe FlyKazia Therapeutics trading resumes
15d ago
KZIA
Kazia Therapeutics trading halted, volatility trading pause
Premium
The Fly
Kazia Therapeutics trading halted, volatility trading pause
15d ago
KZIA
Kazia Therapeutics announces pricing of $50M private placement
Premium
The Fly
Kazia Therapeutics announces pricing of $50M private placement
15d ago
KZIA
Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics
PremiumRatings
Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics
27d ago
KZIA
Closing Bell Movers: Plug Power slips after converible notes offering
PremiumThe Fly
Closing Bell Movers: Plug Power slips after converible notes offering
28d ago
CEG
CARV
Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline
PremiumCompany Announcements
Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline
28d ago
6K
KZIA
Kazia reports results from patient with stage IV TNBC treated with pembrolizumab
PremiumThe Fly
Kazia reports results from patient with stage IV TNBC treated with pembrolizumab
28d ago
KZIA
Kazia Therapeutics Delays 20-F Filing
PremiumCompany AnnouncementsKazia Therapeutics Delays 20-F Filing
2M ago
KZIA
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments and Regulatory Catalysts
2M ago
KZIA
Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Strategic Drug Approval and Licensing Initiatives
2M ago
KZIA
Kazia Therapeutics to request FDA Type C meeting
PremiumThe Fly
Kazia Therapeutics to request FDA Type C meeting
2M ago
KZIA
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
PremiumRatings
Strategic Advancements and Potential in Oncology: Kazia Therapeutics’ Buy Rating Driven by Novel PD-L1 Degrader and AI-Driven Paxalisib Development
2M ago
KZIA
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
PremiumCompany Announcements
Kazia Therapeutics Partners with QIMR Berghofer for Innovative PD-L1 Degrader Program
2M ago
6K
KZIA
Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1
PremiumThe Fly
Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1
2M ago
KZIA
Kazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib
PremiumCompany AnnouncementsKazia Therapeutics Reports Significant Tumor Reduction in TNBC Patient with Paxalisib
3M ago
6K
KZIA
Kazia Therapeutics price target raised to $20 from $15 at Maxim
Premium
The Fly
Kazia Therapeutics price target raised to $20 from $15 at Maxim
3M ago
KZIA
Kazia Therapeutics’ paxalisib combination shows tumor reduction
Premium
The Fly
Kazia Therapeutics’ paxalisib combination shows tumor reduction
3M ago
KZIA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >